Heineken Warns UK Pubs Weight-Loss Drugs Could Cut Beer and Cider Sales
The brewer told British hospitality customers that GLP-1 medicines such as Wegovy could mean fewer pints and smaller serves
By AXY Lifestyle Desk ·
Key points
- Heineken has warned British bars and pubs that weight-loss drugs such as Ozempic and Wegovy could reduce beer and cider sales.
- The company said GLP-1 medication could reduce the desire to drink, which could result in fullness and fewer serves of pints.
- Heineken suggested promoting half pints, offering low- and zero-alcohol options and pairing drinks with small plates of food.
- The brewer said GLP-1 users are becoming more purposeful in their choices and are not simply replacing alcohol.
Heineken, the world’s second-largest brewer, has warned British bars and pubs that the boom in weight-loss drugs could lead to a fall in sales of beer and cider. In a presentation sent to UK hospitality customers earlier this month, the company said the use of GLP-1 medication, including Ozempic and Wegovy, could reduce people’s desire to drink alcohol. That, it added, could result in “fullness and fewer serves” of pints in pubs and bars.
The document was revealed by Reuters. It suggested that the GLP-1 era could make the tradition of the multi-pint drinking session a less frequent occurrence in Britain’s pubs. For an industry built on rounds of drinks and long evenings, that is a pointed warning, and it has come from one of the biggest names on the bar.
Heineken is headquartered in the Netherlands. It said the presentation was part of its regular engagement with UK businesses, and that its aim was to help them understand how consumer habits were evolving. The warning is direct. It names a specific group of medicines and ties them to a particular pattern of drinking, which is what makes it useful for a landlord to read closely.
How Weight-Loss Medicines Reached the Pint Glass
GLP-1 is short for glucagon-like peptide-1. It is a hormone the body makes naturally in the gut, and it plays a part in regulating appetite and blood sugar after eating. Medicines in this class copy its effects. They slow how quickly the stomach empties and send signals to the brain that help people feel full sooner and for longer.
Ozempic and Wegovy both contain semaglutide, which is a GLP-1 medicine. Ozempic is mainly prescribed for type 2 diabetes, while Wegovy is approved for weight management. The two brand names are often used interchangeably in everyday conversation, which can blur the fact that they are prescribed for different purposes. Both are given by injection, and both are used by people who want a medical route to losing weight rather than relying on diet and exercise alone.
Those effects matter for drinking because alcohol is often consumed at the same moments when appetite is strongest, such as the start of a meal or the middle of a long night out. Heineken’s presentation makes that connection. It said the medicines could reduce the desire to drink alcohol, which could then change how much people order.
The speed of uptake is what has caught the attention of the drinks industry. Heineken cited research by JP Morgan that found 10 million people in the US turned to the medication last year as they looked for a quick solution to weight loss. That figure comes from the US, not Britain, so it cannot tell a UK landlord how many regulars are taking these drugs. It does show the scale of demand that brewers are now trying to read.
What Heineken Told UK Venues to Do
The advice in the presentation was practical. Heineken suggested promoting half pints, offering low- and zero-alcohol options, and pairing drinks with small plates of food. Without changes of that kind, the company warned, venues could face declines in customer visits and spending.
Half pints are a simple lever. A bar that displays a half-pint option beside the full serve gives a customer who wants less an easy way to order without feeling they have cut back in front of friends. Low- and zero-alcohol drinks offer a choice for people who still want the taste of a beer or cider but not the alcohol. Food pairings keep people in the venue for longer, and they could lift the amount each guest spends even when the drinks order is smaller.
The last point matters most to the business. A pub can absorb a quiet weekday. A steady drop in how much each customer spends across an evening is harder to recover from, particularly in venues where drinks sales provide much of the income.
Why a Smaller Order Can Hurt More Than a Lost Customer
A pint poured is a sale. A half pint is a smaller one. If a drinker who once had three pints now has one and a half, a pub may keep the customer but lose much of the money that customer used to spend. That is what makes the change hard to spot. A boycott shows up quickly in empty tables. A gradual move to smaller serves shows up as a bar that is still busy, with a quieter till.
The multi-pint session is the format most exposed. A group that once stayed for four rounds might now order two rounds and a plate of food, and the room may still look full at ten o’clock. For a pub built around long sociable evenings, the pattern of spending matters as much as the number of people inside. Heineken’s warning that the multi-pint session could become less frequent points directly at that risk.
For ordinary drinkers, the shift may feel personal rather than commercial. Someone who has started taking a weight-loss medicine may find that their usual pint no longer sits right, or that a second drink feels like one too many. Whether that is the medicine, a wider decision to drink less or both, is not something a bartender can see. What the bar can see is the order.
The trade has adjusted before. Over the years, pubs have had to respond to changing tastes, from a wider range of soft drinks to a growing choice of alcohol-free options. The GLP-1 question adds a new factor: a medicine that may change appetite and the wish for a drink in ways a landlord cannot easily measure from behind the bar.
Smaller Serves, Lower Alcohol and Premium Drinks
Heineken said it has identified several trends among GLP-1 users. They include choosing smaller serves, drinking lower-alcohol products and buying more premium drinks. The company’s view is that these customers are not simply swapping one drink for another.
A Heineken spokesperson said: “Our latest consumer research suggests GLP-1 users are not simply replacing alcohol.” The spokesperson added: “They are becoming more purposeful in their choices and broadening their preferences.”
The company also said these behaviours are not unique to GLP-1 users. In its account, they reflect broader consumer trends towards health and wellbeing, moderation, choice and more intentional consumption that it is seeing across its markets. That framing is significant. If the change is part of a wider move towards moderation, the drinks industry is not only facing a fall in demand. It is being asked to supply a different kind of drink, one that is smaller, lighter in alcohol or sold alongside food.
That also means the opportunity may lie in the range, not only in the volume. For a brewer with lagers, ciders and lower-alcohol options, the question becomes which products sit on the bar and in the fridge, and how they are priced and presented to a customer who is thinking about one drink rather than four.
Heineken’s Brands in the Middle of the Shift
Heineken owns its eponymous lager, along with brands such as Amstel, the Mexican lager Sol and Strongbow cider. That spread covers standard lager, a Mexican lager and cider, which gives the company a presence across several parts of the market. It also gives it a direct stake in what pubs choose to pour.
The presentation was a document shared with trade customers, not a public campaign. Even so, its content shows how large drinks companies are reading the effect of weight-loss medicines on their business. For brewers, the drugs are not only a health story. They are a question about which products will sell over the next few years, and which ones pubs will still want to stock.
How 2027 Could Show Whether Pints Are Really Falling
Heineken said it will continue to monitor how these behaviours evolve in 2027. Its spokesperson said: “We see some changes in consumption behaviour among (GLP-1) users and will continue to monitor how these behaviours evolve in 2027.” The spokesperson also said: “Consumer behaviour is evolving in response to a range of broader trends. GLP-1 is one of the developments we are monitoring.”
The next test is whether these changes show up in pub and bar takings, not just in surveys and presentations. If sales of half pints and low-alcohol drinks rise while total beer and cider volumes fall, that would support Heineken’s view that customers are changing their habits rather than leaving the pub. If the decline is steeper, the warning could prove to be an early sign of a larger reset.
For drinkers, the change may be easy to see. A pint could become a half, a soft drink might sit beside the lager, and a small plate could arrive with the second round. For venues, the question is whether smaller orders can carry the same business, and whether a new generation of customers will want the same kind of night out at all. Those answers will take more than one season to show, and the company has tied its own next review to 2027.
Questions and answers
Why could weight-loss drugs reduce beer sales?
Heineken said GLP-1 medicines such as Ozempic and Wegovy could reduce the desire to drink alcohol. That could result in fullness and fewer serves of pints in pubs and bars.
What did Heineken tell UK pubs and bars to do?
Heineken suggested promoting half pints, offering low- and zero-alcohol options and pairing drinks with small plates of food. It warned that without changes of that kind, venues could see declines in customer visits and spending.
What are GLP-1 drugs?
GLP-1 is short for glucagon-like peptide-1, a hormone the body makes naturally in the gut. Medicines in this class copy its effects and help people feel full sooner and for longer. Ozempic and Wegovy both contain semaglutide.
Will Heineken keep tracking the impact?
Heineken said it will continue to monitor how consumer behaviour among GLP-1 users evolves in 2027. It said GLP-1 is one of several developments it is watching.
Topics: Heineken, GLP-1 drugs, Wegovy, Ozempic, UK pubs, beer sales, alcohol consumption
Sources: The Guardian Lifestyle